Asparaginase in the treatment of non-ALL hematologic malignancies Ashkan EmadiHania ZokaeeEdward A. Sausville Review Article 11 February 2014 Pages: 875 - 883
Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy Aiwen WuYongning JiaJiafu Ji Original Article 25 March 2014 Pages: 885 - 893
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study) Tadahiro ShojiEriko TakatoriToru Sugiyama Original Article Open access 01 March 2014 Pages: 895 - 901
A phase I clinical and pharmacokinetic study evaluating vinflunine in combination with epirubicin as first-line treatment in metastatic breast cancer S. ChanM. CamponeL. Nguyen Original Article 14 March 2014 Pages: 903 - 910
Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1) Jan Hendrik HooijbergGerrit JansenGodefridus J. Peters Original Article 05 March 2014 Pages: 911 - 917
Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy Marta SimóAndreas A. ArgyriouJordi Bruna Original Article 12 March 2014 Pages: 919 - 923
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression Massimo MaffezziniFabio CampodonicoMatteo Puntoni Original Article 01 March 2014 Pages: 925 - 930
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors Kelly K. CurtisJohn SarantopoulosRamesh K. Ramanathan Original Article Open access 08 March 2014 Pages: 931 - 941
Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience Yuka KatoKatsuyuki HottaKatsuyuki Kiura Original Article 16 March 2014 Pages: 943 - 950
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors Amita PatnaikPatricia M. LoRussoColin D. Weekes Original Article 17 March 2014 Pages: 951 - 960
Preclinical antileukemic activity, toxicology, toxicokinetics and formulation development of triptolide derivative MRx102 John M. FidlerJinhua AnMichael Andreeff Original Article 12 March 2014 Pages: 961 - 974
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma Oscar ArrietaDiego López-MacíasJosé-Francisco Corona-Cruz Original Article 01 April 2014 Pages: 975 - 982
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation Xin HongJames P. O’DonnellNorman L. Lehman Original Article 14 March 2014 Pages: 983 - 990
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer Islam R. YounisDaniel J. GeorgeWilliam P. Petros Original Article 12 March 2014 Pages: 991 - 997
Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma A. Thiery-VuilleminG. MouilletB. Royer Original Article 30 March 2014 Pages: 999 - 1007
Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients Carlos Pérez-RuixoJosé E. PerisBelén Valenzuela Original Article 25 March 2014 Pages: 1009 - 1020
Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure Suh-Young LeeHye-Ryun KangSang Heon Cho Original Article 03 April 2014 Pages: 1021 - 1029
No clinically significant drug interactions between lenalidomide and P-glycoprotein substrates and inhibitors: results from controlled phase I studies in healthy volunteers Nianhang. ChenDaniel WeissMaria Palmisano Original Article Open access 22 March 2014 Pages: 1031 - 1039
Pharmacokinetics, placenta, and brain uptake of paclitaxel in pregnant rats Na-Young LeeKyung-Bok LeeYoung-Sook Kang Original Article 18 March 2014 Pages: 1041 - 1045
Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis Toru AoyamaKazuhiro NishikawaAkira Tsuburaya Original Article Open access 21 March 2014 Pages: 1047 - 1054
The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro Michele VisentinErsin Selcuk UnalI. David Goldman Original Article 29 March 2014 Pages: 1055 - 1062
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Ji Yun LeeSung Hee LimMyung-Ju Ahn Original Article 25 March 2014 Pages: 1063 - 1070
A phase I study of oral ixabepilone in patients with advanced solid tumors John F. DeekenJohn L. MarshallPatricia M. LoRusso Original Article 25 March 2014 Pages: 1071 - 1078
Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer Junichi HasegawaJunichi NishimuraMasaki Mori Clinical Trial Report 05 March 2014 Pages: 1079 - 1087
DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development Eric D. ShahBrandon M. A. FischC. Patrick Reynolds Short Communication 25 March 2014 Pages: 1089 - 1093